Skip to main content
OpenTrials
Completed

NCT Number: NCT03705793

Effectiveness of Mometasone Nasal Irrigation for Chronic Rhinosinusitis

Chronic rhinosinusitis (CRS) affects up to 12.5% of the US population and has a significant disease burden. The recommended medical management of CRS includes large-volume, low-pressure saline lavage, systemic antibiotics, and intranasal corticosteroids (INCS). While the efficacy and safety of INCS are well-established for the long-term management of CRS, penetration of INCS beyond the nasal vestibule and into the paranasal sinuses is limited. The aim of this study is to evaluate the effectiveness of mometasone furoate large-volume, low-pressure nasal irrigation for surgery-naive CRS patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Rhinosinusitis (Diagnosis) Allergic Rhinosinusitis Chronic Eosinophilic Rhinosinusitis Disease Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Infections Nose Diseases Otorhinolaryngologic Diseases Paranasal Sinus Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Respiratory Hypersensitivity Respiratory Tract Diseases Respiratory Tract Infections Rhinitis Rhinitis, Allergic Rhinitis, Allergic, Perennial Rhinosinusitis Sinusitis

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Washington University, St Louis, Missouri, United States

Loading trial locations.

About this study

Mometasone furoate nasal spray (MFNS) is a INCS that is used in the management of CRS. The overall goal of this proposed research project is to optimize topical delivery of MF to the paranasal sinuses in surgery-naive CRS patients through the use of high-volume, low-pressure nasal saline irrigation. The investigators will be conducting a single-site, double-blinded, placebo-controlled randomized clinical trial (RCT) in which we propose to evaluate the effectiveness of MF nasal irrigation compared to MF nasal spray.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

12-weeks or longer of two or more of the following signs and symptom consistent with CRS:

  • mucopurulent drainage(anterior, posterior, or both)
  • nasal obstruction (congestion)
  • facial pain-pressure-fullness
  • and decreased sense of smell

AND inflammation documented by one or more of the following findings:

  • purulent mucus or edema in the middle meatus or ethmoid region
  • radiographic imaging showing inflammation of the paranasal sinuses.

Exclusion criteria

  • inability to speak or understand English
  • nasal polyps
  • history of nasal or sinus surgery
  • comorbid mucociliary conditions
  • dependence on prolonged corticosteroid therapy for comorbid conditions, such as asthma and chronic obstructive pulmonary disease
  • history of oral or systematic antibiotic use in the past 2 weeks
  • history of allergy to MF or other topical steroids
  • pregnant or breastfeeding
  • participants with a baseline SNOT-22 score of 9 or less will be excluded due to inability to achieve a minimally clinically improved difference pre- and post-intervention.

Treatment and study plan

Mometasone Furoate Nasal Irrigation

Drug

Participants will undergo an 8-week treatment course that includes nasal saline irrigation with mometasone powder and placebo nasal spray.

Mometasone nasal spray

Drug

Participants will undergo an 8-week treatment course that includes placebo saline irrigation with mometasone nasal spray.

Other names: Nasonex

Primary outcomes

  1. Change in Sino-Nasal Outcome Test Scores (SNOT-22)

    Time frame: Change from Baseline to Week 8

    The change in Sino-Nasal Outcome Test scores (SNOT-22) scores pre- and post-treatment between the two arms was measured. The Sino-Nasal Outcome Test asks subjects to rate how "bad" their rhinosinusitis is by using a 0-5 point scale with 0=no problem, 1=very mild problem, 2=mild or slight problem, 3=moderate problem, 4=severe problem, 5=problem as bad as it can be. The SNOT includes 22 questions (symptoms and social/emotional consequences of rhinosinusitis), each of which are rated from 0 to 5 for a minimum score of 0 to maximum score of 110, with higher scores representing worse outcome.

    All relevant time points used in the calculation in the Time Frame (e.g., 'baseline and 8 weeks")

Secondary outcomes

  1. Number of Participants Who Score <3 on the Clinical Global Impression Scale

    Time frame: Week 8

    CGI asks subjects to rate their overall response to treatment using a 7-point Likert scale with anchors of 1=very much improved, 4=no change, and 7=very much worse.

  2. Change in Nasal Endoscopic Findings Using the Lund-Kennedy Grading System

    Time frame: Change from Baseline to Week 8

    A board-certified otolaryngologist will perform a nasal endoscopic examination pre- and post-intervention and findings recorded using the Lund-Kennedy grading system.

    The The Lund Kennedy System grades the pathologic state of the nasal cavity based on the presence of polyps, nasal discharge, and mucosal edema.

    Polyps graded from 0 to 2 (0=absent, 1=limited to middle meatus, 2=extending to nasal cavity) Discharge graded from 0 to 2 (0=absent, 1=thin/clear, 2=thick) Edema graded from 0 to 2 (0=absent, 1=mild/moderate, 2=polypoid degeneration). Scores are added for each side of the nose with a minimum score of 0 and maximum score of 12 with higher scores indicating more severe sinonasal inflammation.

Sponsors and collaborators

Lead sponsor

Washington University School of Medicine

Other

Registry information

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Oct 15, 2018
Registry last updated
Jun 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.